Navigation Links
InfuSystem Holdings Modifies Bylaws to Align with Corporate Governance Best Practices

MADISON HEIGHTS, Mich., May 30, 2012 /PRNewswire/ -- InfuSystem Holdings, Inc. (NYSE MKT: INFU), the leading national provider of infusion pumps and related services for the healthcare industry, announced today it has implemented a number of substantive bylaw changes that enhance shareholder rights, as well as better align with ISS recommendations for corporate governance, including:

  • Reducing the percentage of shareholders required to call a special meeting of shareholders to 10 percent.  It previously required a majority;
  • Shortening the notice requirement of shareholder director nominations and meeting proposals to 60-90 days from 90-120 days in advance of the anniversary of the prior year's meeting;
  • Allowing a majority of shareholders to act by written consent rather than the prior 100% requirement, providing a means for investors to consider and vote on matters that could arise between annual meetings; and
  • Changing to a majority, rather than plurality, voting requirement for election of director nominees.

The Board also voted to withdraw the Rights Agreement, dated as of November 12, 2010 (i.e., the "poison pill"), which will be effected shortly.

"The InfuSystem Board has affirmed its commitment to transparent communication, strong corporate governance practices, and the highest ethical standards consistent with our stewardship responsibilities," Executive Board Chairman Ryan Morris stated.  "Boards, after all, serve at the pleasure of their shareholders.  We firmly believe that acting in an owner-oriented fashion is the most responsible approach."

The Company also reported that its newly constituted Board of Directors, elected by shareholders, received more than 99% of the votes cast for election at this year's annual shareholders meeting on May 25, 2012.

"We appreciate this overwhelming vote of confidence from our shareholders," added Morris.  "The duly elected Board, working in concert with the new management team here, have, in short order, established the foundation from which the Company intends to achieve operational and strategic growth, and increase shareholder value."

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. is the leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providers.  Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, and Ontario, Canada.  The Company's stock is traded on the NYSE MKT under the symbol INFU.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements.  These risks and uncertainties include general economic conditions, as well as other risks, detailed from time to time in the Company's publicly filed documents.

Additional information about InfuSystem Holdings, Inc. is available at

Jonathan P. Foster
Chief Financial Officer


SOURCE InfuSystem Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InfuSystem Provides Update on Special Meeting of Stockholders
2. InfuSystem Postpones Announcement of Fourth Quarter and Fiscal Year 2011 Earnings
3. InfuSystem Holdings, Inc. To Announce First Quarter 2012 Financial Results On May 21, 2012
4. InfuSystem Holdings, Inc. Receives Letter From NYSE MKT Regarding Timely Notice Of Record Date For 2012 Annual Meeting Of Stockholders
5. InfuSystem Holdings, Inc. Reports $14.3 Million of Revenues And $1.6 Million Of EBITDA For The First Quarter Of 2012
6. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
7. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
8. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
9. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
10. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2009 Results
11. Lincare Holdings Inc. Extends Terms of Employment Agreements with Executive Officers
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
Breaking Medicine News(10 mins):